SG11201501386TA - Sirna and their use in methods and compositions for the treatment and/or prevention of eye conditions - Google Patents
Sirna and their use in methods and compositions for the treatment and/or prevention of eye conditionsInfo
- Publication number
- SG11201501386TA SG11201501386TA SG11201501386TA SG11201501386TA SG11201501386TA SG 11201501386T A SG11201501386T A SG 11201501386TA SG 11201501386T A SG11201501386T A SG 11201501386TA SG 11201501386T A SG11201501386T A SG 11201501386TA SG 11201501386T A SG11201501386T A SG 11201501386TA
- Authority
- SG
- Singapore
- Prior art keywords
- sirna
- prevention
- compositions
- treatment
- methods
- Prior art date
Links
- 108020004459 Small interfering RNA Proteins 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 230000002265 prevention Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Ophthalmology & Optometry (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1215857.2A GB201215857D0 (en) | 2012-09-05 | 2012-09-05 | siRNA and their use in methods and compositions for the treatment and/or prevention of eye conditions |
| PCT/EP2013/068245 WO2014037377A1 (en) | 2012-09-05 | 2013-09-04 | Sirna and their use in methods and compositions for the treatment and/or prevention of eye conditions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201501386TA true SG11201501386TA (en) | 2015-03-30 |
Family
ID=47136985
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201501386TA SG11201501386TA (en) | 2012-09-05 | 2013-09-04 | Sirna and their use in methods and compositions for the treatment and/or prevention of eye conditions |
Country Status (30)
| Country | Link |
|---|---|
| US (1) | US9808479B2 (en) |
| EP (1) | EP2893019B1 (en) |
| JP (2) | JP2015529210A (en) |
| KR (1) | KR102136539B1 (en) |
| CN (2) | CN104640988A (en) |
| AU (1) | AU2013311781B2 (en) |
| BR (1) | BR112015004469B8 (en) |
| CA (1) | CA2883040C (en) |
| CL (1) | CL2015000537A1 (en) |
| CY (1) | CY1121000T1 (en) |
| DK (1) | DK2893019T3 (en) |
| EC (1) | ECSP15009391A (en) |
| ES (1) | ES2685346T3 (en) |
| GB (1) | GB201215857D0 (en) |
| HK (1) | HK1212377A1 (en) |
| HR (1) | HRP20181079T1 (en) |
| HU (1) | HUE040096T2 (en) |
| IL (1) | IL237389B (en) |
| IN (1) | IN2015DN02501A (en) |
| LT (1) | LT2893019T (en) |
| MX (1) | MX362854B (en) |
| PE (1) | PE20150619A1 (en) |
| PL (1) | PL2893019T3 (en) |
| PT (1) | PT2893019T (en) |
| RS (1) | RS57620B1 (en) |
| RU (1) | RU2663100C2 (en) |
| SG (1) | SG11201501386TA (en) |
| SI (1) | SI2893019T1 (en) |
| WO (1) | WO2014037377A1 (en) |
| ZA (1) | ZA201501494B (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6165723B2 (en) | 2011-06-30 | 2017-07-19 | アローヘッド ファーマシューティカルズ インコーポレイテッド | Compositions and methods for inhibiting gene expression of hepatitis B virus |
| AU2016306275A1 (en) | 2015-08-07 | 2018-02-08 | Arrowhead Pharmaceuticals, Inc. | RNAi therapy for Hepatitis B virus infection |
| JOP20170161A1 (en) | 2016-08-04 | 2019-01-30 | Arrowhead Pharmaceuticals Inc | RNAi Agents for Hepatitis B Virus Infection |
| JP6994061B2 (en) | 2019-02-15 | 2022-01-14 | ノバルティス アーゲー | Preparation of 4- (7-hydroxy-2-isopropyl-4-oxo-4H-quinazoline-3-yl) -benzonitrile |
| CA3130038A1 (en) | 2019-02-15 | 2020-08-20 | Novartis Ag | Methods for treating ocular surface pain |
| EP4043014A4 (en) * | 2019-10-04 | 2023-10-11 | Senju Pharmaceutical Co., Ltd. | Pharmaceutical drug containing heterocyclidene acetamide derivative |
Family Cites Families (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4343794A (en) | 1980-05-06 | 1982-08-10 | Mt. Sinai | Method of reducing intraocular pressure with salts of vanadic acid |
| US4652586A (en) | 1980-11-07 | 1987-03-24 | The General Hospital Corporation | Selective beta-2 adrenergic antagonists for the treatment of glaucoma |
| US4617299A (en) | 1983-12-19 | 1986-10-14 | Knepper Paul A | Method for the prevention of ocular hypertension, treatment of glaucoma and treatment of ocular hypertension |
| US5242943A (en) | 1984-03-28 | 1993-09-07 | William J. Louis | 3-aminopropoxyphenyl derivatives, their preparation and pharmaceutical compositions containing them |
| US4812448A (en) | 1984-10-22 | 1989-03-14 | Knepper Paul A | Method for the prevention of ocular hypertension, treatment of glaucoma and treatment of ocular hypertension |
| US4757089A (en) | 1985-06-14 | 1988-07-12 | Massachusetts Eye And Ear Infirmary | Increasing aqueous humor outflow |
| US5075323A (en) | 1988-08-24 | 1991-12-24 | Aktiebolaget Hassle | Compounds including omeprazole in the treatment of glaucoma |
| US5260059A (en) | 1989-04-14 | 1993-11-09 | The State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of Oregon Health Sciences University | Treatment of open-angle glaucoma by modulation matrix metalloproteinases and their inhibitor |
| US6372249B1 (en) | 1991-12-16 | 2002-04-16 | Baylor College Of Medicine | Senscent cell-derived inhibitors of DNA synthesis |
| US5464866A (en) | 1992-08-17 | 1995-11-07 | Alcon Laboratories, Inc. | Substituted hydrindanes for the treatment of angiogenesis-dependent diseases |
| US5545626A (en) | 1994-01-19 | 1996-08-13 | The Trustees Of Columbia University In The City Of New York | Method of treating glaucoma with oligonucleotides |
| US5585401A (en) | 1994-12-09 | 1996-12-17 | The Reents Of The University Of California | Method for enhancing outflow of aqueous humor in treatment of glaucoma |
| US20020055536A1 (en) | 1996-09-26 | 2002-05-09 | Dewitte Robert S. | System and method for structure-based drug design that includes accurate prediction of binding free energy |
| US6489307B1 (en) | 1998-09-14 | 2002-12-03 | University Of Florida | Antisense compositions targeted to β1-adrenoceptor-specific mRNA and methods of use |
| WO2000044914A1 (en) | 1999-01-28 | 2000-08-03 | Medical College Of Georgia Research Institute, Inc. | Composition and method for in vivo and in vitro attenuation of gene expression using double stranded rna |
| US6365576B1 (en) | 1999-06-24 | 2002-04-02 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Method for inhibiting herpes infection |
| CZ308053B6 (en) | 2000-12-01 | 2019-11-27 | Max Planck Gesellschaft | Isolated double-stranded RNA molecule, process for producing it and its use |
| US20020165158A1 (en) | 2001-03-27 | 2002-11-07 | King George L. | Methods of modulating angiogenesis |
| US20040209832A1 (en) | 2001-11-30 | 2004-10-21 | Mcswiggen James | RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA) |
| US20050148530A1 (en) | 2002-02-20 | 2005-07-07 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA) |
| US20070049543A1 (en) | 2001-05-18 | 2007-03-01 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of 11 beta-hydroxysteroid dehydrogenase-1 (11 beta-HSD-1) gene expression using short interfering nucleic acid siNA |
| WO2003059267A2 (en) | 2001-12-21 | 2003-07-24 | Rhode Island Hospital | SELECTIVE 11β-HSD INHIBITORS AND METHODS FOR USE THEREOF |
| US7294504B1 (en) | 2001-12-27 | 2007-11-13 | Allele Biotechnology & Pharmaceuticals, Inc. | Methods and compositions for DNA mediated gene silencing |
| GB2406568B (en) | 2002-02-20 | 2005-09-28 | Sirna Therapeutics Inc | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
| AU2003207708A1 (en) | 2002-02-20 | 2003-09-09 | Sirna Therapeutics, Inc. | Rna interference mediated inhibition of map kinase genes |
| ES2397060T3 (en) | 2002-04-18 | 2013-03-04 | Opko Pharmaceuticals, Llc | Means and methods for specific modulation of target genes in the eye |
| US20040115641A1 (en) | 2002-12-11 | 2004-06-17 | Isis Pharmaceuticals Inc. | Modulation of ROCK 1 expression |
| WO2004009796A2 (en) | 2002-07-24 | 2004-01-29 | Immusol Incorporated | Single promoter system for making sirna expression cassettes and expression libraries using a polymerase primer hairpin linker |
| EP1534840A4 (en) | 2002-07-24 | 2006-01-18 | Immusol Inc | Novel sirna gene libraries and methods for their production and use |
| SI3222724T1 (en) | 2002-08-05 | 2019-03-29 | Silence Therapeutics Gmbh | Further novel forms of interfering rna molecules |
| US20040029275A1 (en) | 2002-08-10 | 2004-02-12 | David Brown | Methods and compositions for reducing target gene expression using cocktails of siRNAs or constructs expressing siRNAs |
| CA2500224C (en) | 2002-09-25 | 2015-04-28 | University Of Massachusetts | In vivo gene silencing by chemically modified and stable sirna |
| KR20120038546A (en) | 2002-11-01 | 2012-04-23 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | Compositions and methods for sirna inhibition of hif-1 alpha |
| DE10322662A1 (en) | 2002-11-06 | 2004-10-07 | Grünenthal GmbH | New DNA type 10-23 enzyme, useful for treating e.g. pain, and related short interfering RNA, directed against the vanillin receptor or picorna viruses, contains specific nucleotide modifications for improved stability |
| WO2006006948A2 (en) | 2002-11-14 | 2006-01-19 | Dharmacon, Inc. | METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY |
| US7250496B2 (en) | 2002-11-14 | 2007-07-31 | Rosetta Genomics Ltd. | Bioinformatically detectable group of novel regulatory genes and uses thereof |
| DK2284266T3 (en) | 2002-11-14 | 2014-01-13 | Thermo Fisher Scient Biosciences Inc | SIRNA MOLECULE MOD TP53 |
| US20060257851A1 (en) | 2002-11-26 | 2006-11-16 | Itzhak Bentwich | Bioinformatically detectable group of novel viral regulatory genes and uses thereof |
| US20040167090A1 (en) | 2003-02-21 | 2004-08-26 | Monahan Sean D. | Covalent modification of RNA for in vitro and in vivo delivery |
| GB0307206D0 (en) | 2003-03-28 | 2003-04-30 | Axordia Ltd | Hyperproliferation |
| US20040198640A1 (en) | 2003-04-02 | 2004-10-07 | Dharmacon, Inc. | Stabilized polynucleotides for use in RNA interference |
| WO2004099372A2 (en) | 2003-05-01 | 2004-11-18 | University Of Florida | Anti-scarring ribozymes and methods |
| US20040224405A1 (en) | 2003-05-06 | 2004-11-11 | Dharmacon Inc. | siRNA induced systemic gene silencing in mammalian systems |
| EP1636342A4 (en) | 2003-06-20 | 2008-10-08 | Isis Pharmaceuticals Inc | Oligomeric compounds for use in gene modulation |
| GB2406856B (en) | 2003-10-07 | 2005-10-19 | Renovis Inc | Amide compounds as ion channel ligands and uses thereof |
| WO2005045037A2 (en) | 2003-10-23 | 2005-05-19 | Sirna Therapeutics, Inc. | RNA INTERFERENCE MEDIATED INHIBITION OF 5-ALPHA REDUCTASE AND ANDROGEN RECEPTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| KR20050039573A (en) | 2003-10-23 | 2005-04-29 | 주식회사 태평양 | Thiourea derivative-containing pharmaceutical composition having improved solubility and bioavailability |
| US20050208658A1 (en) | 2003-11-21 | 2005-09-22 | The University Of Maryland | RNA interference mediated inhibition of 11beta hydroxysteriod dehydrogenase-1 (11beta HSD-1) gene expression |
| JP5838017B2 (en) * | 2003-12-03 | 2015-12-24 | コーダ セラピューティクス， インコーポレイテッド | Antisense compounds targeted against connexins and methods of use thereof |
| US7544803B2 (en) | 2004-01-23 | 2009-06-09 | Amgen Inc. | Vanilloid receptor ligands and their use in treatments |
| EP1711510A4 (en) | 2004-02-05 | 2008-11-26 | Intradigm Corp | Rnai therapeutics for treatment of eye neovascularization diseases |
| GB0403600D0 (en) | 2004-02-18 | 2004-03-24 | Trinity College Dublin | Methods and reagents for treating disease |
| CA2559161C (en) | 2004-03-12 | 2013-06-11 | Alnylam Pharmaceuticals, Inc. | Irna agents targeting vegf |
| KR101147147B1 (en) | 2004-04-01 | 2012-05-25 | 머크 샤프 앤드 돔 코포레이션 | Modified polynucleotides for reducing off-target effects in rna interference |
| WO2005117938A2 (en) | 2004-04-13 | 2005-12-15 | Regents Of The University Of Minnesota | Methods of treating ocular conditions |
| EP1768954A4 (en) | 2004-06-24 | 2008-05-28 | Incyte Corp | 2-methylpropanamides and their use as pharmaceuticals |
| JP5192234B2 (en) | 2004-08-10 | 2013-05-08 | アルナイラム ファーマシューティカルズ， インコーポレイテッド | Chemically modified oligonucleotide |
| AU2005276245C1 (en) | 2004-08-23 | 2015-02-26 | Sylentis S.A.U. | Treatment of eye disorders characterized by an elevated introacular pressure by siRNAs |
| TW200639252A (en) | 2005-02-01 | 2006-11-16 | Alcon Inc | RNAi-mediated inhibition of ocular hypertension targets |
| US7947660B2 (en) | 2005-03-11 | 2011-05-24 | Alcon, Inc. | RNAi-mediated inhibition of frizzled related protein-1 for treatment of glaucoma |
| GB0521351D0 (en) | 2005-10-20 | 2005-11-30 | Genomica Sau | Modulation of TRPV expression levels |
| AU2007286545A1 (en) * | 2006-08-24 | 2008-02-28 | Alcon Research, Ltd. | RNAi-mediated inhibition of gremlin for treatment of IOP-related conditions |
| WO2009023025A1 (en) | 2007-08-13 | 2009-02-19 | Board Of Trustees Of Southern Illinois University | Methods for treatment and prevention of ototoxicity by sirna |
| TW200927192A (en) | 2007-11-19 | 2009-07-01 | Alcon Res Ltd | Use of TRPV1 receptor antagonists for treating dry eye and ocular pain |
| CN201337650Y (en) * | 2009-01-06 | 2009-11-04 | 河北科技大学 | Disposable single dose medicine liquid container |
| EP2390327A1 (en) * | 2010-05-27 | 2011-11-30 | Sylentis S.A. | siRNA and their use in methods and compositions for the treatment and/or prevention of eye conditions |
-
2012
- 2012-09-05 GB GBGB1215857.2A patent/GB201215857D0/en not_active Ceased
-
2013
- 2013-09-04 PE PE2015000282A patent/PE20150619A1/en not_active Application Discontinuation
- 2013-09-04 BR BR112015004469A patent/BR112015004469B8/en active IP Right Grant
- 2013-09-04 RS RS20180877A patent/RS57620B1/en unknown
- 2013-09-04 IN IN2501DEN2015 patent/IN2015DN02501A/en unknown
- 2013-09-04 DK DK13759707.6T patent/DK2893019T3/en active
- 2013-09-04 SI SI201331090T patent/SI2893019T1/en unknown
- 2013-09-04 EP EP13759707.6A patent/EP2893019B1/en active Active
- 2013-09-04 ES ES13759707.6T patent/ES2685346T3/en active Active
- 2013-09-04 MX MX2015002802A patent/MX362854B/en active IP Right Grant
- 2013-09-04 PT PT13759707T patent/PT2893019T/en unknown
- 2013-09-04 SG SG11201501386TA patent/SG11201501386TA/en unknown
- 2013-09-04 CN CN201380046215.0A patent/CN104640988A/en active Pending
- 2013-09-04 CA CA2883040A patent/CA2883040C/en active Active
- 2013-09-04 CN CN201810353730.8A patent/CN108354944A/en active Pending
- 2013-09-04 WO PCT/EP2013/068245 patent/WO2014037377A1/en active Application Filing
- 2013-09-04 RU RU2015112121A patent/RU2663100C2/en active
- 2013-09-04 JP JP2015530372A patent/JP2015529210A/en active Pending
- 2013-09-04 LT LTEP13759707.6T patent/LT2893019T/en unknown
- 2013-09-04 US US14/425,459 patent/US9808479B2/en active Active
- 2013-09-04 PL PL13759707T patent/PL2893019T3/en unknown
- 2013-09-04 HU HUE13759707A patent/HUE040096T2/en unknown
- 2013-09-04 AU AU2013311781A patent/AU2013311781B2/en active Active
- 2013-09-04 KR KR1020157006165A patent/KR102136539B1/en active IP Right Grant
-
2015
- 2015-02-24 IL IL237389A patent/IL237389B/en active IP Right Grant
- 2015-03-04 ZA ZA2015/01494A patent/ZA201501494B/en unknown
- 2015-03-04 CL CL2015000537A patent/CL2015000537A1/en unknown
- 2015-03-12 EC ECIEPI20159391A patent/ECSP15009391A/en unknown
-
2016
- 2016-01-05 HK HK16100039.5A patent/HK1212377A1/en unknown
-
2018
- 2018-05-09 JP JP2018090693A patent/JP6742362B2/en active Active
- 2018-07-11 HR HRP20181079TT patent/HRP20181079T1/en unknown
- 2018-08-10 CY CY181100845T patent/CY1121000T1/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1204988A1 (en) | Methods and compositions for preventing or treating ophthalmic conditions | |
| HK1210957A1 (en) | Effluz inhibitor compositions and methods of treatment using the same | |
| HK1198631A1 (en) | Prevention and treatment of ocular conditions | |
| EP2831001A4 (en) | Water treatment compositions and methods of use | |
| HK1212377A1 (en) | Sirna and their use in methods and compositions for the treatment and/or prevention of eye conditions sirna / | |
| GB201217296D0 (en) | Method of treatment and/or prevention | |
| SI2576782T1 (en) | Sirna and their use in methods and compositions for the treatment and/or prevention of eye conditions | |
| PL2854910T3 (en) | Ceramide levels in the treatment and prevention of infections | |
| ZA201307058B (en) | Use of polyaminoisoprenyl derrivatives in antobiotic or antisertic treatment | |
| EP2800568A4 (en) | Compositions, methods of use, and methods of treatment | |
| IL222482A0 (en) | Methods and compositions for the treatment of fluid accumulation in and/or under the retina | |
| HK1211983A1 (en) | Sirna and their use in methods and compositions for the treatment and/or prevention of eye conditions sirna / | |
| ZA201408058B (en) | Compositions and methods for the treatment of epilepsy | |
| HK1206598A1 (en) | Eprotirome for use in the prevention and or treatment of hair disorders and compositions thereof | |
| PL2862576T3 (en) | Microorganisms and compositions comprising them for use in the treatment or prevention of mastitis | |
| IL243237A0 (en) | Methods and compositions for the treatment of fluid accumulation in and/ or under the retina | |
| AU2012902937A0 (en) | Composition for prevention and treatment of eye disorder |